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If you anticipate the revision of this manuscript to take more than 60 days, please notify the editorial office .  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Epithelial-to-mesenchymal transition (EMT) is critical for embryonic development and wound healing, and occurs in fibrotic disease and carcinoma. Here, we show that EMT also occurs within the bulge, the epithelial stem cell (eSC) niche of human scalp hair follicles (HFs), during the inflammatory permanent alopecia, lichen planopilaris (LPP).
We show for the first time that a molecular EMT signature can be experimentally induced in healthy human eSCs in situ by antagonizing E-cadherin, combined with TGF-ß1, EGF, and interferon-γ administration. Moreover, induction of EMT within primary human eSCs can be prevented and even partially reversed ex vivo by PPAR-γ agonists, likely through suppression of TGFβ signaling pathway. Furthermore, we show that PPAR-γ agonism also attenuates the EMT signature even in lesional LPP HFs ex vivo.
Thus, we introduce LPP as a model disease for pathological EMT in human adult eSCs, report the first preclinical assay for therapeutically manipulating eSC EMT within a healthy human (mini-)organ and show that PPAR-γ agonists are promising agents for suppressing and partially reversing EMT in human HF eSCs ex vivo, including in LPP. Epithelial-to-mesenchymal transition (EMT) is a physiological feature during embryogenesis and wound healing, but also occurs during pathological phenomena such as the malignant transformation of epithelial cells, carcinoma metastasis, and several fibrotic diseases (Nieto et al., 2016 , Stone et al., 2016 . During EMT, epithelial cells gradually assume a fibroblast-like morphology as a result of transcriptional repression of E-cadherin via E-box binding factors, such as SNAI1 (SNAIL), SNAI2 (SLUG) and TWIST, and upregulation of mesenchymal hallmark proteins such as vimentin and fibronectin (Nieto et al., 2016, Zeisberg and Neilson, 2009 ).
EMT is frequently investigated using immortalised cell lines that display an abnormal karyotype and epigenetic modifications not observed in normal cells (Serrano-Gomez et al., 2016) . Primary cells are also utilised, even though these often adopt a wound healing-like spontaneous EMT response when cultured in vitro (Nieto et al., 2016 , Stone et al., 2016 . Therefore, the cellular behavior under these artificial conditions might not accurately reflect EMT as it occurs in vivo. Moreover, while existing animal models for studying EMT in vivo provide a native tissue environment, it is unclear how well these mimic human EMT under physiological or pathological conditions, or predict whether experimental therapies will translate to the clinic (Pasquier et al., 2015) . This caveat is particularly relevant in the skin, given the many anatomical and functional differences between rodent and human skin.
Finally, though EMT events can be studied, in patient biopsies, these typically catch only the final stages in the stepwise and initially reversible EMT continuum (Nieto et al., 2016 , Pasquier et al., 2015 , Serrano-Gomez et al., 2016 , Stone et al., 2016 , Zeisberg and Neilson, 2009 ).
Page 5 of 43
Journal of Investigative Dermatology   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Purba et al., 2014) and show scarring hair loss (alopecia) when these eSCs get destroyed within their immunologically privileged niche, the bulge (Harries et al., 2013, Harries and Paus, 2010) . Therefore, we aimed to explore whether human scalp HFs can serve as an instructive model system for studying the EMT process in eSCs in live human tissue.
For this, we focused on lichen planopilaris (LPP), one of the most frequently encountered primary cicatrial alopecias (PCA), a group of relatively rare, but clinically important inflammatory alopecias that result in skin scarring and permanent hair loss Paus, 2010, Sinclair, 2016) . While current evidence suggests that LPP results from a CD8+ T celldriven attack on eSCs that have lost their relative immune privilege (Harries et al., 2013) the loss of eSCs alone does not explain the typically associated scarring. Indeed, when K15+ve bulge eSCs were selectively deleted in mice, the resulting alopecia was not accompanied by scarring (Ito et al., 2005) . However, abnormal expression of Snail has been identified in the fibrotic dermis of frontal fibrosing alopecia, another variant of PCA (Nakamura and Tokura, 2010) , inviting the hypothesis that EMT may play a role in PCAs (Nakamura and Tokura, 2011 
Results and Discussion
Lesional LPP hair follicles display morphological and ultrastructural signs of EMT within their epithelial stem cell niche
First, we re-examined our archive of LPP patient samples (Harries et al., 2013) and
complemented this with biopsy material from additional LPP patients. Morphological analysis of the bulge compartment of lesional LPP HFs (as indicated by the arrector pili muscle insertion point ( Figure 1A ) and other previously defined human bulge markers (Purba et al., 2014) revealed a breakdown of the usual, very tight segregation between the eSC compartment and the surrounding HF mesenchyme in lesional LPP HFs; occasionally even the highly pathological presence of spindled cells of myofibroblast-like appearance could be demonstrated within the bulge epithelium itself (Figure 1B) .
These findings were followed-up by transmission electron microscopy. This confirmed the presence of fibroblastoid cells within lesional bulge epithelium and revealed putative collagen filaments within the cytoplasm of bulge keratinocytes (Figure 1C) , a pathological ultrastructural phenomenon previously reported during EMT of ocular epithelium (Ogawa et al., 2009) .  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 bulge epithelium compared to non-lesion bulge areas from the same individual by quantitative real-time PCR (qRT-PCR was performed on mRNA that had previously been selectively obtained from the bulge by laser capture microdissection (Harries et al., 2013) ).
This approach elucidated the expression of several EMT related genes in some of our LPP lesional biopsies, with no detectable expression in any healthy biopsy from the same patients.
This was the case for TWIST1 (2/6 patients), ZEB2 (3/6), FN1 (fibronectin; 4/6), ACTA2 (αsmooth muscle actin; 4/6), EMP1 (3/6) ( Supplemental Table 1 ). Other EMT related transcripts were found in both the LPP lesional and healthy bulge, such as CD44
( Supplemental Table 1 ), which is a known epithelial bulge marker (Szabo et al., 2013) .
More surprising was the presence of SNAI2 and ZEB1, which might indicate that some (presumably reversible) EMT occurs long before clinical presentation. We did not observe an EMT signature in every single donor and this may reflect the severity of disease, or the transient nature of EMT. However, the fact that we sometimes detect EMT markers in LPP lesional bulge, but never from an unaffected region from the same donor, adds weight to our hypothesis.
To more fully explore this, we assessed the protein expression of key EMT markers within the bulge of lesional LPP HFs compared to scalp from healthy volunteers via quantitative immunohistomorphometry (Harries et al., 2013) (Figure 1D and Supplemental Figure 1 ). This showed E-cadherin protein expression in the bulge of lesional LPP HFs to be significantly reduced, while the number of vimentin+ or fibronectin+ cells was significantly increased. When we also investigated the protein expression of early EMT markers, SNAIL protein-positive cells were significantly increased in the bulge epithelium of LPP, predominantly showing the expected nuclear immunoreactivity (Dubois-Marshall et al., Figure 1) . Moreover, SLUG protein immunoreactivity was also significantly increased in LPP HFs, while a trend towards increased expression of TWIST protein was also observed ( Figure 1C) . Interestingly, SLUG protein was expressed predominantly within the cytoplasm, a phenomenon previously reported in Barrett's metaplasia (Jethwa et al., 2008) and ameloblastoma (Siar and Ng, 2014) . ZEB1, αSMA and CD44 protein expression did not differ significantly between lesional LPP and healthy control bulges (Supplemental Figure 2) .
2011) (Supplemental

Cells undergoing EMT within the bulge express the eSC marker Keratin 15+
Next, we performed dual immuno-fluorescence microscopy of vimentin with the prototypic bulge SC marker, keratin 15 (K15) (Purba et al., 2014) . This documented that at least some of the vimentin-expressing cells in the bulge of lesional LPP HFs represent indeed eSCs ( Figure   1E ). These analyses also independently confirmed our previous finding that K15 is markedly reduced (Harries et al., 2013) . With patient biopsies we are unable to conclusively prove the origin of these vimentin/K15 double-positive cells. However, invasion of dermal fibroblasts into the bulge epithelium has not been reported outside of malignancy, and we are not aware of any evidence that non-malignant, non-transformed human mesenchymal cells (such as dermal fibroblasts) can ever express the eSC-associated keratin 15 in situ. Therefore, we conclude that the only plausible explanation for vimentin/K15 double-positive cells is that eSCs underwent EMT within the bulge. Thus, our data clearly show that at least some human eSCs in the bulge epithelium of HFs affected by LPP undergo EMT, thus potentially contributing to the extensive scarring seen in LPP and likely other PCAs. Therefore, future LPP management should also attempt to effectively inhibit the EMT of bulge eSCs before it becomes irreversible. Our findings are in line with the recent report that EMT also occurs in human HF epithelium in situ during keloid formation, as indicated by abnormal vimentin expression (Yan et al., 2015) . Thus, it is conceivable that anti-EMT therapies developed by studying LPP as a model disease may also become applicable to other diseases characterized by excessive scar tissue formation.
EMT can be induced in healthy human HFs ex vivo
However, given that LPP is an orphan disease (ORPHA:525, http://www.orpha.net), clinical material is difficult to obtain, and patients typically seek medical attention only during latestage disease (Sinclair, 2016) . Therefore, we wondered if it would be possible to experimentally mimic the early molecular changes associated with EMT in the bulge of microdissected, organ-cultured healthy human HFs (Langan et al., 2015) .
We designed a cocktail of recognized EMT-promoting agents containing; epidermal growth factor (EGF), transforming growth factor-β1 (TGF-β1), interferon-γ (IFN-γ), and the selective E-cadherin inhibiting peptide SWELYYPLRANL (peptide A) (Segal and Ward, 2017 ), and exposed organ-cultured, full-length human anagen VI HFs which had been microdissected with their bulge area intact to this "EMT cocktail" (see supplemental methods for details).
Intriguingly, after only 3 days, this rapidly, significantly, and reproducibly reduced Ecadherin transcript and protein expression in the bulge epithelium of "EMT cocktail"-treated 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 HFs ex vivo, compared to vehicle-treated control HFs (Figure 2A) . Vice versa, vimentin and SLUG transcript and protein expression were significantly increased (Figure 2) , replicating the changes observed in the bulge of lesional LPP. Extending the cultures to day 6 did not further increase these effects, suggesting that a maximal induction of EMT had occurred.
Omitting any one of the "EMT cocktails" constituents reduced the potency of EMT induction (Supplemental Figure 3) .
To our knowledge, this is the first report of both, experimentally induced EMT in adult human eSCs within their physiological SC niche and in a healthy human (mini-)organ ex vivo. Given the critical importance of the eSC niche and its surrounding mesenchyme for HF development, growth, and survival (Sennett and Rendl, 2012) , this simple, but clinically relevant assay opens up new possibilities for interrogating and manipulating the as yet obscure (patho-)biology of human eSC that undergo EMT.
Moreover, as expected from the general EMT literature (Nieto et al., 2016 , Pasquier et al., 2015 , Serrano-Gomez et al., 2016 , Stone et al., 2016 , Zeisberg and Neilson, 2009 ), our assay identifies the suppression of E-cadherin-mediated signaling and stimulation by TGF-ß1, EGF, and IFN-γ as four molecular key signals sufficient to induce EMT in primary human eSCs in situ. This is well in line with the fact that TGF-β1 is typically overexpressed in fibrotic diseases (Walraven et al., 2017) and that IFN-γ is overexpressed in/around lesional LPP HFs (Harries et al., 2013) . Therefore, our HF organ culture results encourage one to preferentially target in subsequent studies these specific pathways when attempting to therapeutically counteract EMT-related HF scarring and loss of eSCs.
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Journal of Investigative Dermatology   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Next, we explored the utility of our new HF organ culture EMT assay for the identification of promising drugs that can counteract EMT in the eSC zone of human HFs. For this, we turned to the PPAR-γ agonist, pioglitazone, i.e. a widely prescribed insulin-sensitizing agent primarily used for treating type 2 diabetes mellitus (DeFronzo et al., 2011) . Pioglitazone reportedly can inhibit ocular EMT (Hatanaka et al., 2012) . Moreover, compared to healthy skin, LPP skin shows a defect in PPAR-γ expression , and PPAR-γ agonists have been advocated as a third line therapy for LPP (Mirmirani and Karnik, 2009 ).
Since PPAR-γ expression in the bulge itself does not differ between lesional and non-lesional LPP HFs (Harries et al., 2013) , even diseased HFs should still be susceptible to PPAR-γ modulation. HFs treated only with the "EMT cocktail" showed the expected EMT induction signature, namely decreased E-cadherin alongside increased vimentin and SLUG expression ex vivo. Instead, when pioglitazone (30µM) was administered to the culture medium one day before the "EMT cocktail", E-cadherin and vimentin expression did not significantly differ from that of vehicle-treated control HFs (Figure 3A and Supplemental Figure 4) . Moreover, Slug protein expression was significantly reduced by pioglitazone pretreatment compared to EMT-cocktail alone, although it was only partially repressed compared to vehicle treatment.
The investigated pioglitazone dose was not capable of reversing the molecular EMT signature, when pioglitazone was added 72h after experimental EMT induction ( Figure 3A) .
Epithelial cells grown in vitro readily adopt an EMT-like state (Stone et al., 2016) , thus to explore the mechanisms by which Pioglitazone might inhibit EMT, we treated isolated hair follicle keratinocytes in monolayer culture. Following stimulation with Pioglitazone PPAR-γ is increased, with a downregulation of TGF-β1, SMAD2 and SMAD3 (Figure 3B) . This effect is blocked by the co-treatment with the PPAR-γ antagonist GW9662 (Figure 3B ). In addition, PPAR-γ stimulation was also enhanced when TGF-B1 expression was suppressed via siRNA (Figure 3C) . To further confirm this mechanism we assessed paired lesional vs uninvolved whole tissue biopsies from LPP patients. We show that TGF-β1, SMAD2 and SMAD3 are all upregulated, while PPAR-γ is downregulated (Figure S5) , adding further support for TGF-β signaling as a key mechanism for EMT in LPP, and the potential of PPAR-γ agonism in the treatment of this and perhaps other fibrotic diseases.
PPAR-γ stimulation by N-Acetyl-GED partially reverses EMT signature in normal and
LPP HFs
Given that pioglitazone has adverse effects that question its utility for treating hair diseases (Ramot et al., 2015) , we also investigated the EMT-modulatory activity of N-Acetyl-GED (AGED), a topically applicable PPAR-γ modulator that is undergoing clinical trials in acne vulgaris (www.clinicaltrialsregister.eu/ctr-search/trial/2016-000540-33/HU). This showed that all three tested concentrations of AGED significantly reduced the number of SLUG+ or vimentin+ cells compared to HFs treated with the EMT cocktail alone (Figure 4A and Supplemental Figure 6 ). Remarkably, this was seen when AGED was added either before (prevention), or after (rescue) EMT induction, suggesting that AGED may even be capable of partially reversing early-stage EMT. However, AGED effects on bulge E-cadherin expression were unimpressive (Figure 4A ) E-cadherin could not be rescued within the experimental window by either Pioglitazone or AGED, suggesting that either the 3 day experimental window was insufficient to promote E-cadherin expression, or that additional signals are required to restore Ecadherin functionality. The lack of a dose dependent response with AGED was surprising though has previously been observed (Ramot et al., 2014) . The reason for this might be due to measuring indirect effects of PPAR-γ activation, or variability in the levels of EMT induced within each HF. Finally, to understand whether AGED could reverse EMT in LPP we collected fresh biopsy tissue from the lesional site of 2 LPP patients. After 5 days, tissue cultured with 0.1mM AGED showed a significant improvement in the expression of E-cadherin and SLUG, whose expression patterns tended towards that of healthy skin, while a non-significant trend was observed with Vimentin ( Figure 4B ).
The reduction of experimentally induced EMT in the human bulge ex vivo with pioglitazone or AGED treatment demonstrates that our HF assay is well-suited as a screening system for identifying candidate drugs that may be repositioned for therapeutically counteracting EMT in human eSCs. Also, our results are well in line with evidence that PPAR-γ agonists attenuate experimentally induced fibrosis in other organs (Aoki et al., 2009 , Ramot et al., 2015 , possibly through the suppression of TGF-β signaling (Hatanaka et al., 2012) . AGED is of particular interest in this context, since this PPAR-γ modulator may also protect human HF eSCs from apoptosis and stimulates keratin 15 expression in human scalp HF eSCs ex vivo (Ramot et al., 2014) .
Given that LPP skin shows significantly reduced PPAR-γ transcription compared to healthy human scalp skin (Supplemental Figure S5) , LPP patients may be at a (constitutive?) disadvantage in suppressing EMT in their HF eSCs, prior to infiltration of CD8+ T cells into the bulge (Figure 5) . Thus, sufficient PPAR-γ−mediated signalling may well be critical for HF eSC maintenance and homeostasis, namely in individuals predisposed to developing LPP.
This further encourages one to systematically explore PPAR-γ modulators as complementary 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (classified as a reduction in symptoms, diminished signs of inflammation and cessation of hair loss progression) was reported in 50-70% cases, although complete remission was seen less frequently and scarring was not reversed (Mirmirani and Karnik 2009; Baibergenova and Walsh 2012; Mesinkovska, Tellez et al. 2015 ) (Spring, Spanou et al. 2013) .
Moreover, as Pioglitazone and AGED show slightly different efficiencies at inhibiting various EMT target genes, a combination of different PPAR-γ agonists might be used in concert to supress EMT most effectively.
In summary, our study introduces LPP as a model disease for pathological EMT in human adult eSCs, and shows that an EMT signature can be experimentally induced and therapeutically manipulated in these human eSCs within their niche, namely by PPAR-γ agonists. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 All samples were taken with informed patient consent.
Materials and Methods
Study approval
Human tissue
Human scalp skin was obtained with informed consent, with studies performed at the Salford Royal NHS Foundation Trust /University of Manchester. Diagnosis of LPP was determined via standard clinical and histopathological criteria Paus, 2010, Sinclair, 2016) .
Many of the LPP specimens had been diagnostically classified and assessed during our previous study (Harries et al., 2013) . Lesional specimens were taken from clinically inflamed edges of alopecia containing a reduced density of hairs and were fixed in formalin for paraffin embedding (FFPE) (see Supplemental Table 2 for clinical features of each patient).
Paired lesional and non-lesional specimens were also obtained from this cohort and snapfrozen in liquid nitrogen. Clinically healthy control samples (n =4) were obtained from surplus occipital scalp skin of patients undergoing elective hair restoration surgery (mean age 50 years).
Quantitative RT-PCR
In order to permit optimal comparisons with the results from our previous study, the same RNA samples used previously (Harries et al., 2013) were used in the current study. qRT-PCR was performed on a StepOne Plus TM Real-Time PCR system using Taqman gene expression assays. Whole tissue biopsies from paired lesion and uninvolved areas from 3 additional donors was used to profile TGF-β signalling, with RNA isolation and qRT-PCR as previously described (Panicker et al., 2012) . For details of probes used see Supplemental Table 3 . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Human hair follicle organ culture
Serum-free organ culture of human anagen scalp HFs was performed as previously described (Langan et al., 2015) , from the occipital or temporal scalp of patients undergoing hair restoration surgery. Individual full length HFs were dissected from the surrounding tissue or microdissected from the tissue and incubated overnight in culture media (Williams E media supplemented with Insulin (10µg/ml), Hydrocortisone (40ng/ml), L-glutamine (2mM), Penicillin (100µg/ml) and Streptomycin (100U/ml)). The following day HFs present in anagen VI were transferred to media supplemented with either vehicle or a cocktail of agents known to promote EMT (TGF-β1 (3ng/ml), EGF (10ng/ml), interferon-γ (500IU/ml)) or to inhibit E-cadherin-mediated cell-cell contact (H-SWELYYPLRANL-NH2; Peptide A, 500nM (Segal and Ward, 2017) . HFs were harvested into OCT embedding compound and stored at -80°C prior to use. In co-culture studies, pioglitazone (30µM; Enzo Life Sciences) or AGED (0.01, 0.1, 1mM; PPM Services S.A.) was added either 24h prior to (prevention) or 72h following (rescue) addition of the EMT cocktail.
Culture of LPP tissue
A single 4mm punch was taken from the LPP lesional site in two female donors (44 and 78 years old). The biopsy was cut into half with each piece of tissue grown in culture media (described above). Tissue was dosed with vehicle or 0.1mM AGED on days 1 and 3, with the tissue harvested at day 5 and snap frozen in cryomatrix. Primary human hair follicle outer root sheath cells were purchased from ScieCell Research Labs (Carlsbad, CA) and cultured as previously described (Panicker et al., 2012) . Cells at passage 3 or 4 were seeded at 0.6x10 6 cells per well and treated with either 10 µM Pioglitazone, 10 µM Pioglitazone plus 10 µM GW9662, or vehicle for 16-24 hours. Data are taken from 3 independent experiments and analysed using one way Anova.
Culture of human outer root sheath keratinocyte cells
50 µM of TGF-β1 siRNA was added to ORSK cells for 24 hrs compared to empty vector alone (OriGene).
Immunohistochemistry and quantitative immunohistomorphometry
6µm sections were used for immunohistochemistry of FFPE and frozen samples. Heatinduced antigen retrieval (Citrate or Tris-EDTA) was performed as required. For IHC protocol summary, see Supplemental Table 4 ). Immunostaining intensity of the HF bulge was assessed by quantitative immunohistomorphometry using NIH image software ("Image J", NIH, Bethesda, Maryland), as previously described (Harries et al., 2013) . Only HFs where the bulge region could be definitively identified were used for analysis, which for biopsy samples this was confirmed by positioning of the arrector pili muscle, while for organ cultured HFs the co-localisation with α6 integrin was used to mark the basement membrane.
For the AGED experiments, Vimentin, SLUG, and E-cadherin immunoreactivity was evaluated in 9-12 HFs/donor in 3 independent experiments (3 different donors) for the rescue or prevention assay. For this assays, pooled data from 3 donors are presented as Fold increase of Mean±SEM. Statistical analysis was performed using Mann-Whitney and p<0.05 as regarded as significant. 
Transmission electron microscopy
Samples were prefixed with 2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 M phosphate buffer and fixed with 1% osmium tetroxide in the same buffer. Samples were then dehydrated via ethanol gradient, immersed in propylene oxide, and embedded in resin.
Ultrathin sections were stained with tannic acid-uranyl acetate solution and lead citrate, and observed using the H-7500 apparatus (Hitachi, Japan).
Statistics
Non-paired samples were compared using two-sample Student's t-test assuming equal or unequal variance after F-test. Human HF organ culture groups were compared using one-way ANOVA. For the AGED human HF organ culture, pooled data from 3 donors are presented as fold-change compared to vehicle and analyzed by Mann-Whitney test. Data are expressed as mean ±SEM; p values of <0.05 were deemed significant.
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PPAR-g agonist
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